Patrick Dolezal
Stock Analyst at LifeSci Capital
(4.52)
# 1,029
Out of 4,491 analysts
185
Total ratings
43.9%
Success rate
16.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Patrick Dolezal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NGNE Neurogene | Maintained: Buy | $60 → $65 | $36.63 | +77.47% | 11 | Jul 7, 2026 | |
| IBIO iBio, Inc. | Maintained: Buy | $5 | $1.52 | +228.95% | 12 | Jul 1, 2026 | |
| KOD Kodiak Sciences | Rated: Buy | $65 | $38.92 | +67.03% | 9 | Jun 29, 2026 | |
| MBX MBX Biosciences | Maintained: Buy | $91 | $61.74 | +47.39% | 6 | Jun 18, 2026 | |
| IMMX Immix Biopharma | Initiated Coverage: Buy | $19 | $11.00 | +72.73% | 1 | Jun 17, 2026 | |
| OCS Oculis Holding AG | Maintained: Buy | $45 | $13.58 | +231.37% | 9 | Jun 6, 2026 | |
| SLGL Sol-Gel Technologies | Maintained: Buy | $184 | $74.00 | +148.65% | 2 | May 28, 2026 | |
| RCKT Rocket Pharmaceuticals | Rated: Buy | $12 | $4.12 | +191.62% | 44 | May 9, 2026 | |
| SRZN Surrozen | Rated: Buy | $37 → $44 | $22.41 | +96.34% | 5 | May 9, 2026 | |
| GPCR Structure Therapeutics | Rated: Buy | $107 → $104 | $54.57 | +90.60% | 12 | May 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $60 | $69.91 | n/a | 21 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $0.6539 | n/a | 25 | Nov 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $14 | $3.46 | n/a | 12 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $17 → $16 | $0.8799 | n/a | 5 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $39 | $39.26 | n/a | 1 | Dec 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $27 → $25 | $4.31 | n/a | 2 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €10.00 → €25.00 | $3.76 | n/a | 8 | Jun 16, 2020 |
Neurogene
Jul 7, 2026
Maintained: Buy
Price Target: $60 → $65
Current: $36.63
Upside: +77.47%
iBio, Inc.
Jul 1, 2026
Maintained: Buy
Price Target: $5
Current: $1.52
Upside: +228.95%
Kodiak Sciences
Jun 29, 2026
Rated: Buy
Price Target: $65
Current: $38.92
Upside: +67.03%
MBX Biosciences
Jun 18, 2026
Maintained: Buy
Price Target: $91
Current: $61.74
Upside: +47.39%
Immix Biopharma
Jun 17, 2026
Initiated Coverage: Buy
Price Target: $19
Current: $11.00
Upside: +72.73%
Oculis Holding AG
Jun 6, 2026
Maintained: Buy
Price Target: $45
Current: $13.58
Upside: +231.37%
Sol-Gel Technologies
May 28, 2026
Maintained: Buy
Price Target: $184
Current: $74.00
Upside: +148.65%
Rocket Pharmaceuticals
May 9, 2026
Rated: Buy
Price Target: $12
Current: $4.12
Upside: +191.62%
Surrozen
May 9, 2026
Rated: Buy
Price Target: $37 → $44
Current: $22.41
Upside: +96.34%
Structure Therapeutics
May 9, 2026
Rated: Buy
Price Target: $107 → $104
Current: $54.57
Upside: +90.60%
Dec 11, 2023
Rated: Buy
Price Target: $60
Current: $69.91
Upside: n/a
Nov 11, 2023
Maintained: Buy
Price Target: $6
Current: $0.6539
Upside: n/a
Aug 10, 2023
Rated: Buy
Price Target: $14
Current: $3.46
Upside: n/a
Mar 9, 2023
Maintained: Buy
Price Target: $17 → $16
Current: $0.8799
Upside: n/a
Dec 11, 2022
Maintained: Buy
Price Target: $39
Current: $39.26
Upside: n/a
Mar 8, 2021
Maintained: Buy
Price Target: $27 → $25
Current: $4.31
Upside: n/a
Jun 16, 2020
Reiterated: Buy
Price Target: €10.00 → €25.00
Current: $3.76
Upside: n/a